The company develops and commercializes inhalable solutions to treat respiratory diseases. TFF has two lead drug candidates in the clinic: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder, and continues to expand its pipeline through collaborations with pharmaceutical companies, academic institutions and government partners.
Cyborg Score Rationale
Status uncertainty significantly impacts confidence. Crunchbase flags permanent closure while other sources lack recent (2025-2026) operational updates. Clinical-stage biotech with limited commercial revenue and technology-dependent pipeline creates execution risk. However, 120+ patents and institutional partnerships provide asset value.
Top Insights
Proprietary Thin Film Freezing (TFF) technology addresses significant unmet need for poorly water-soluble drug formulations affecting ~33% of major pharmaceuticals globally
Dual lead candidates (Voriconazole and Tacrolimus inhalation powders) targeting high-value respiratory indications with significant commercial potential
Patent portfolio of 120+ issued or pending patents provides intellectual property moat for TFF platform
Strategic partnerships with academic institutions (University of Texas Austin) and government entities (NIH/NIAID) validate technology platform and reduce development risk
Named Competitors
Respiratory Drug Products — Inhalation and respiratory disease treatments
Inhalation Devices — Pulmonary disease therapies and delivery systems
Dry Powder Formulations — Advanced inhalation drug delivery platforms
Recent Developments
(July 2022) Expanded R&D operations with 3,500+ sq ft Austin facility focused on downstream processing, manufacturing scale-up, and biologics applications
Open the full interactive TFF Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.